01:35 PM EST, 12/31/2024 (MT Newswires) -- Mountain Valley MD ( MVMDF ) were fluctuating on Tuesday after the company provided a year-end business update on its commercialization progress across its three core areas: Nutraceuticals, Agriculture and Husbandry Animals/Aquatic Species.

The company said it is actively working with the lead manufacturer on multiple proprietary formulation projects, namely an Opioid Use Disorder (OUD) Adjunct Therapy and a Fenugreek Glycosides Testosterone Product. The company also expects Circadian, who entered into a license agreement with the company, to begin reporting and making royalty payments starting in the first quarter of 2025.

Under agriculture, in line with Panamanian Agrarius product registration obtained in early December, the company is negotiating a supply agreement with a distributor who currently provides agricultural products nationally in Panama. The company also expects revenue made from contracted farms for the Agrarius product used under the Performance Guarantee Program, in the first quarter of the 2025.

Under its Husbandry Animals category, the company's licensee expects ongoing manufacturing and sales activity of its SoluvecTM 1%, through 2025.

Shares of the company have fluctuated a bit but having been down $0.005 or 16%, at $0.025 on the Canadian Securities Exchange they were last up 0.0015 or 7.7% at 0.0209.